SCHEMBL367918

SCHEMBL367918

O=C(O)c1ccc(COc2ccc3ccncc3c2)cc1

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 2/20 0.76
NR4A2 P43354 4/20 0.52
NR4A1 P22736 1/20 0.52
NR4A3 Q92570 1/20 0.52
RXRA P19793 6/20 0.52
RXRB P28702 6/20 0.52
NPC1 O15118 3/20 0.52
RAB9A P51151 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
POLB P06746 1/20 0.52
RXRG P48443 2/20 0.52
MAPT P10636 1/20 0.52
CYSLTR1 Q9Y271 1/20 0.52
TSHR P16473 1/20 0.51
CYP26A1 O43174 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP4F2 P78329 1/20 0.49
CYP4A11 Q02928 1/20 0.49
F2 P00734 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22480788 0.86 MRGPRX4 (1.00) MRGPRX4NR4A2RAB9ASMN1; SMN2
SCHEMBL6993654 0.83 MRGPRX4 (0.70) MRGPRX4NPC1RAB9ACYP3A4F2
SCHEMBL10236856 0.81 MRGPRX4 (0.55) MRGPRX4NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL1412056 0.79 ALOX5 (0.67) MRGPRX4NPC1RAB9ACYP3A4F2
SCHEMBL18906034 0.78 NR4A2 (0.72) NR4A2NR4A1NR4A3RXRARXRB
SCHEMBL18546031 0.77 MRGPRX4 (0.69) MRGPRX4NR4A2NR4A1NR4A3NPC1
SCHEMBL16742694 0.77 PTPN7 (0.66) MRGPRX4POLBMAPTTSHRCYP26A1
SCHEMBL24124842 0.77 RAB9A (0.65) MRGPRX4NPC1RAB9ASMN1; SMN2
SCHEMBL29488886 0.76 MRGPRX4 (0.56) MRGPRX4CYP3A4
SCHEMBL1403704 0.76 MRGPRX4 (0.56) MRGPRX4CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9102621-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-11 US disclosed
EP-2593431-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-19 EP disclosed
EP-2593431-A2 CHEMICAL COMPOUNDS Pfizer Limited (GB) 2013-05-22 EP disclosed
US-20130109708-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012007869-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109708-A1 Chemical Compounds SCN1A, SCN1B, SCN7A MRGPRX4 761/4885NR4A2 1933/4885NR4A1 1197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.